Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma

NCT02306850 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Unresectable Malignant Neoplasm
Melanoma
Metastatic Melanoma
Stage IV Melanoma
Stage III Melanoma

Interventions

DRUG: Pembrolizumab

Sponsor

St. Louis University